SAM
CLDX icon

Sectoral Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Sectoral Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-16,879
Closed -$914K – 64
2017
Q1 		$914K Buy
+16,879
New +$879K 0.11% 58
2014
Q2 		– Sell
-93,927
Closed -$24.9M – 67
2014
Q1 		$24.9M Sell
93,927
-54,586
-37% -$20.9M 1.02% 32
2013
Q4 		$53.9M Buy
148,513
+85,545
+136% +$33M 2.33% 17
2013
Q3 		$33.5M Buy
+62,968
New +$21.6M 1.61% 22

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sectoral Asset Management's CLDX Position: Q2 2017 in Review

Sectoral Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 16,879 shares — an estimated $914K sold.

Sectoral Asset Management first reported a position in CLDX in Q3 2013 and held it in 4 quarters. The position peaked at $53.9M in Q4 2013. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • Sectoral Asset Management reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Sectoral Asset Management sold 16,879 Celldex Therapeutics shares in Q2 2017, an estimated $914K.
  • Sectoral Asset Management first reported a position in Celldex Therapeutics in Q3 2013 and held it in 4 quarters.
  • Sectoral Asset Management's Celldex Therapeutics position peaked at $53.9M in Q4 2013.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Sectoral Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.